
usd may pm et
summari compani one largest world-wide provid integr dialysi servic
patient suffer chronic kidney failur
price-to-earnings oper ep
risk assess reflect stabl demand dialysi
servic driven rise senior popul
off-set depend govern payment
payor medicar medicaid
aug ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
lower target price
reflect multipl
oper cash flow estim
premium dva histor forward averag
lift ep
narrow estim
report ep vs beat
 capit iq consensu estim
result driven
increas dialysi treatment per day
even downtick at-hom dialysi
share repurchas partial off-set lower
revenu per treatment dva busi
proven resili impact
far contrari health care provid
given non-opt natur dialysi
decid accept care act fund far
due lesser need health care
organ rest
anticip volum impact
chang mortal transplant and/or new
patient admit result
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview davita inc lead provid dialysi relat servic
patient suffer chronic kidney failur also known end-stag renal diseas esrd
decemb compani oper provid administr servic network
outpati dialysi center year ago state district columbia serv
total approxim patient dva center specif focus provid outpati
hemodialysi decemb also provid hospit inpati hemodialysi servic
exclud physician servic patient approxim hospit throughout
hemodialysi use artifici kidney call dialyz remov certain toxin fluid salt
patient blood togeth machin control extern blood flow monitor certain vital sign
patient hemodialysi treatment occur outpati dialysi center typic last
approxim three one-half hour usual perform three time per week
market profil esrd state advanc renal impair irrevers requir routin
dialysi treatment kidney transplant sustain life treatment option esrd includ
hemodialysi periton dialysi kidney transplant growth procedur driven
age popul increas incid rate diseas caus kidney failur
diabet hypertens lower mortal rate dialysi patient growth rate minor
popul higher-than-averag incid rate esrd
largest competitor freseniu medic group account approxim
outpati dialysi center dialysi industri experienc consolid
last year remain highli competit patient retent continu referr patient
referr sourc hospit nephrologist well acquir develop new
outpati dialysi center import part dva growth strategi
 dialysi busi face intens competit large- medium-s provid
compet directli limit acquisit target individu patient may choos dialyz
physician qualifi provid requir medic director servic mani center
own larg profit dialysi provid own control hospit
non-profit organ hospital-bas non-profit dialysi unit typic difficult
acquir physician-own dialysi center
legal/regulatori issu govern medicar medicaid primari payor
care esrd dialysi patient account dialysi revenu medicar
account major govern revenu esrd payment rate dialysi
establish congress medicar composit rate set center medicar medicaid
servic includ payment dialysi treatment suppli use treatment specifi
laboratori test certain pharmaceut provid paid separ servic
pharmaceut includ erythropoietin epo vitamin analog iron supplement gener
averag cost servic pharmaceut plu small margin base price set medicar
medicar payment rate suffici cover averag cost provid dialysi treatment
cover treatment medicar pay amount set medicar system patient
respons remain case secondari payor cover part
major develop octob california bill ab sign law essenc
elimin chariti support low-incom patient california result bill american kidney
fund akf ceas oper california start januari expect bill neg
impact oper incom million also anticip increas spend
combat new california ballot initi could vote novemb new
initi aim limit revenu dialysi provid earn tie revenu cost
decemb enter agreement sell davita medic group dmg collabor
subsidiari billion cash sale dmg close juli
use net proce sale dmg prepay term debt outstand
financi trend dva dialysi relat lab servic net revenu per treatment
slightli meanwhil patient care cost per treatment fell
growth dva revenu per treatment pressur patient mix
shift away commerci payer dialysi relat lab servic revenu
commerci percentag decreas addit
growth dva cost outpac net medicar rate increas due inflat labor suppli cost
includ increas mainten cost
dva revenu declin compound annual growth rate compound-annual-growth-rate adjust reflect
deconsolid davita medic group dmg ebitda remain approxim flat
billion march compani elev level debt given net debt capit ratio
net debt ebitda ratio divestitur dmg provid relief dva debt
burden net debt ebitda basi year-end although net debt capit remain flat
free cash flow billion sizabl million
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued usd
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook health care servic
sub-industri next year neg
recess concern
impact expect demand typic health care
servic declin significantli yoy
peopl stay home health care
system focu shift address
exampl comment late march
anesthesiolog busi experienc
signific declin elect surgeri
volum driven closur oper
suit facil yet
opportun exampl lab
test provid labcorp quest
relat test
long term even weak macroeconom
condit persist expect demand health
care servic remain rel steadi
compar industri
import health care consum prior
profit health care
servic compani pressur recent
year factor rise wage labor
legislative/regulatori initi
difficult determin rise unemploy
relat effect affect
pressur
believ long-term trend rise
health care spend
incentiv legisl regul
find way control cost health care
servic industri easi target
cost cut exampl initi lower
health care cost includ trump initi
chang payment model dialysi treatment
bipartisan effort tackl surpris bill
unclear chang dialysi
payment affect firm like
long run believ surpris bill
legisl like neg impact
physician outsourc group mednax
limit physician reimburs
struck individu mandat
associ afford act
howev court avoid determin
much remain valid believ
outcom remov possibl
worst-cas scenario health care servic
firm complet
gener benefit increas
insur coverag past sever year
elimin certain provis
could neg impact
industri earli suprem court
agre hear case decis
case like made
earliest believ suprem
court allow remain
minim impact health care
prior anticip
sub-industri ep growth
estim growth rate given
fluiditi volatil current
situat await earn commentari
updat ep expect health
march
declin composit index
 health servic index
gain vs increas
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
treatment growth compani lift adjust oper
incom guidanc rang billion rang
billion primarili due non-recurring benefit low-pric
calcimimet drug commonli use dialysi patient
revenu per treatment increas cost per
treatment decreas primarili due lower calcimimet expens higher
labor product also replac share repurchas plan new billion
share repurchas plan expir date /kevin huang cfa
et cfra maintain hold opinion share
share dialysi provid fell today news presid
trump intend reveal plan wednesday juli encourag kidney
transplant at-hom dialysi treatment accord report politico
 depart human servic hh announc new
payment model aim shift treatment away stand-alone clinic
at-hom treatment goal trump plan increas patient
safeti lower cost expect see continu share price volatil
dialysi provid next day /kevin huang cfa
et cfra keep hold opinion share davita inc
lower target base enterpris valu
ebitda ratio ratio equal three-year
averag ep vs lower consensu estim
lower ep ep
adjust oper incom declin yoy million million
line expect weaker-than-expect volum growth off-set
approxim million temporari tailwind calcimimet price
non-acquir volum growth compani long-term
guidanc volum growth hurt growth kidney
transplant increas competit activ highlight
davita medic group dmg sale clear path
obtain ftc approv allevi concern remind effect
june javier rodriguez succeed long-tenur ceo kent thiri /kevin
analyst research note compani news
pm et cfra maintain hold opinion share davita inc
lower target price reflect
multipl oper cash flow estim premium
dva histor forward averag lift ep
narrow estim
report ep vs beat capit iq consensu
estim result driven increas dialysi
treatment per day even downtick at-hom dialysi share
repurchas partial off-set lower revenu per treatment dva
busi proven resili impact far contrari
health care provid given non-opt natur dialysi
decid accept care act fund far due lesser need
health care organ rest anticip volum
impact chang mortal transplant and/or new patient admit
result /paig meyer
et cfra maintain hold opinion share davita inc
lift target price reflect
multipl oper cash flow estim dva
histor forward averag peak level lift ep
start estim report ep
vs consensu estim driven primarili
increas treatment per day vs quarter year prior
lower expens partial off-set lower revenu per treatment
non-acquir revenu growth quarter flat prior
quarter increas ep outlook approxim due
expect benefit calcimimet partial off-set higher expect cost
ballot initi california forecast oper margin
factor ab labor cost
pressur partial off-set invest integr kidney care data
 analyt reduc cost /paig meyer
et cfra maintain hold opinion share davita inc
rais target price base
enterpris valu ebitda ratio report ep
vs estim larg due million
non-recur benefit lower cost calcimimet rais ep
ep increas
partial off-set increas expect spend combat new ballot
initi california vote upon novemb elect
sinc divestitur dmg group june reduc
outstand share count approxim adjust oper
incom million margin million
consensu expect calcimimet benefit non-acquir
revenu growth flat compar growth level prior two
et cfra maintain hold opinion share davita inc
lift target base enterpris
valu ebitda ratio lower valuat
multipl reflect complet divestitur davita medic group
dmg balanc sheet leverag much healthier look
dmg busi sold ep vs beat consensu
estim driven temporari tailwind low-pric calcimimet
chang ep estim ep
earn releas mostli in-lin expect
compani alreadi pre-announc result prior week /kevin
pm et cfra keep hold opinion share davita inc
share trade midday today announc compani
preliminari result report full earn next thursday
august preliminari result report non-acquir
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
